India’s First Public Interventional Psychiatry Service Integrates Psychedelic Therapies

India Establishes an Interventional Psychiatry Service Including Psychedelics

The launch of an interventional psychiatry service at a public tertiary-care teaching hospital in India represents a significant institutional milestone for psychedelic-assisted interventions in the country. The Center for Neuromodulation and Interventional Psychiatry now offers a range of procedural treatments, including both established neuromodulation techniques and emerging psychedelic therapies, within a mainstream, multispecialty public hospital setting.

This development, as detailed in the October 2026 publication Establishing an Interventional Psychiatry Service in a Public Tertiary-care Teaching Hospital in India, demonstrates growing acceptance of psychedelic-assisted care among Indian psychiatric leadership and provides a practical model for integration in low- and middle-income countries (LMICs).

Mechanisms and Clinical Context: Integrating Neuromodulation and Psychedelic-Assisted Care

Interventional psychiatry is an emerging subspecialty that applies advances in neuroscience and technology to the procedural treatment of psychiatric disorders. While traditional psychiatric care in India has relied on pharmacotherapy and psychotherapy, the new service expands the therapeutic toolkit to include:

• Electroconvulsive therapy (ECT)
• Repetitive transcranial magnetic stimulation (rTMS)
• Theta-burst stimulation
• Transcranial direct current stimulation (tDCS)
• Invasive neuromodulation (in select cases)
• Ketamine and psychedelic-assisted interventions

This integrated approach is informed by a growing body of evidence suggesting that direct or indirect modulation of brain circuits can alleviate symptoms in mood, anxiety, and trauma-related disorders. Notably, the Indian Psychiatric Society (IPS) has published guidelines for ECT, rTMS, and tDCS, but formal protocols for psychedelic-assisted therapy remain in development. The hospital’s initiative thus fills a gap by operationalizing these interventions in a resource-constrained, high-volume public sector context.

Policy and Research Implications for India’s Public Health Sector

The establishment of this service has broad implications for policy, research, and clinical practice in India. First, it signals institutional acceptance of psychedelic-assisted interventions within the country’s influential public health system, which serves as a model for other LMICs. Second, the center’s experience may catalyze the development of national guidelines, ethical frameworks, and regulatory engagement specific to the Indian context.

Importantly, the center’s approach adapts international best practices to local realities—such as workforce limitations, infrastructure constraints, and patient diversity—offering a replicable blueprint for other public hospitals. The inclusion of psychedelic therapies alongside established neuromodulation techniques is particularly notable, as it demonstrates a willingness to innovate within the bounds of public sector medicine, even in the absence of comprehensive local regulatory guidance.

One non-obvious implication is that the operational challenges faced—such as equipment procurement, staff training, and protocol adaptation—are being systematically documented. This real-world implementation data, often lacking in published literature, will be critical for informing future policy and scaling efforts across India and similar settings.

Risks, Unknowns, and Ethical Considerations

The integration of psychedelic-assisted interventions in a public hospital setting introduces several risks and unknowns. While the evidence base for certain psychedelics (e.g., ketamine, psilocybin) is expanding, most studies have been conducted in high-resource, Western contexts. The safety, efficacy, and acceptability of these interventions in diverse Indian populations—many with complex comorbidities and limited access to follow-up care—remain to be fully established.

Potential risks include:

• Adverse psychological reactions or medical complications in vulnerable patients
• Stigma and cultural resistance to psychedelic therapies
• Regulatory uncertainty and lack of formal approval for some substances
• Ethical concerns around informed consent and equitable access

The hospital’s experience underscores the need for robust monitoring, culturally tailored informed consent processes, and ongoing staff training. As the field evolves, close collaboration with regulatory agencies, ethics committees, and patient advocacy groups will be essential to ensure safe and equitable implementation.

Looking Forward: Scaling, Research, and Policy Engagement

The establishment of India’s first public interventional psychiatry service integrating psychedelic therapies is likely to accelerate further research, guideline development, and eventual regulatory engagement. As real-world outcome data and operational lessons are disseminated, other public and private institutions may follow suit, expanding access to innovative psychiatric treatments across India’s vast population.

For researchers and policymakers, the center’s experience provides a unique opportunity to study the effectiveness, safety, and scalability of psychedelic-assisted care in a large, diverse, and resource-constrained health system. For clinicians and administrators, it offers a template for adapting international best practices to local realities. The next phase will require careful balancing of innovation with patient safety, ethical oversight, and system-level sustainability.

How we research / reviewed by Dr. Priya Menon, MBBS, MD (Psychiatry), October 2026